Zimmer Biomet Holdings Management

Management Kriterienprüfungen 2/4

Zimmer Biomet Holdings CEO ist Ivan Tornos , ernannt in Mar 2021, hat eine Amtszeit von 3.67 Jahren. Die jährliche Gesamtvergütung beträgt $10.19M , bestehend aus 9.5% Gehalt und 90.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.013% der Aktien des Unternehmens, im Wert von R$16.73M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.7 Jahre bzw. 6.3 Jahre.

Wichtige Informationen

Ivan Tornos

Geschäftsführender

US$10.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	9.5%
Amtszeit als Geschäftsführer	3.7yrs
Eigentum des Geschäftsführers	0.01%
Durchschnittliche Amtszeit des Managements	3.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.3yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ivan Tornos im Vergleich zu den Einnahmen von Zimmer Biomet Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	n/a	n/a	US$997m
Mar 31 2024	n/a	n/a	US$964m
Dec 31 2023	US$10m	US$969k	US$1b
Sep 30 2023	n/a	n/a	US$474m
Jun 30 2023	n/a	n/a	US$506m
Mar 31 2023	n/a	n/a	US$450m
Dec 31 2022	US$6m	US$823k	US$290m
Sep 30 2022	n/a	n/a	US$366m
Jun 30 2022	n/a	n/a	US$334m
Mar 31 2022	n/a	n/a	US$325m
Dec 31 2021	US$5m	US$731k	US$445m
Sep 30 2021	n/a	n/a	US$834m
Jun 30 2021	n/a	n/a	US$914m
Mar 31 2021	n/a	n/a	US$563m
Dec 31 2020	US$4m	US$730k	-US$11m
Sep 30 2020	n/a	n/a	-US$152m
Jun 30 2020	n/a	n/a	US$37m
Mar 31 2020	n/a	n/a	US$377m
Dec 31 2019	US$4m	US$700k	US$1b
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$359m
Mar 31 2019	n/a	n/a	-US$308m
Dec 31 2018	US$4m	US$113k	-US$379m

Vergütung im Vergleich zum Markt: IvanDie Gesamtvergütung ($USD10.19M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt BR ($USD5.77M).

Entschädigung vs. Einkommen: IvanDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Ivan Tornos (49 yo)

3.7yrs

Amtszeit

US$10,191,476

Vergütung

Mr. Ivan Tornos serves as Independent External Director at PHC Holdings Corporation since September 03, 2021. He joined PHC Holdings Corporation on September 03, 2021. Mr. Tornos serves as Chief Operating...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ivan Tornos	COO, President	3.7yrs	US$10.19m	0.013% R$ 16.7m
Suketu Upadhyay	CFO and Executive VP of Finance	5.3yrs	US$10.38m	0.010% R$ 13.0m
Chad Phipps	Senior VP	17.5yrs	US$2.87m	0.025% R$ 30.8m
Sang Yi	President of Asia Pacific	9.4yrs	US$3.38m	0.0027% R$ 3.3m
Wilfred van Zuilen	Group President of Europe	3.4yrs	US$3.42m	0.0046% R$ 5.8m
Paul Stellato	VP, Controller & Chief Accounting Officer	2.5yrs	keine Daten	0.00069% R$ 859.1k
Shaun Braun	Senior VP & Chief Information and Technology Officer	less than a year	keine Daten	keine Daten
Rachel Ellingson	Senior VP & Chief Administrative Officer	less than a year	keine Daten	0.0034% R$ 4.3m
David DeMartino	Senior VP of Investor Relations	less than a year	keine Daten	keine Daten
Angela Main	Senior VP	9.4yrs	keine Daten	keine Daten
Lori Winkler	Senior VP & Chief Human Resources Officer	3.8yrs	keine Daten	0.0017% R$ 2.1m
David Kunz	Senior Vice President of Global Quality & Regulatory Affairs	7.3yrs	keine Daten	keine Daten

3.7yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: Z1BH34Das Führungsteam des Unternehmens gilt als erfahren (3.7 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ivan Tornos	COO, President	1.3yrs	US$10.19m	0.013% R$ 16.7m
Christopher Begley	Independent Chairman of the Board	12.3yrs	US$409.38k	0.0018% R$ 2.2m
Betsy Bernard	Independent Director	15.8yrs	US$340.26k	0.0027% R$ 3.3m
Robert Hagemann	Independent Director	16.7yrs	US$358.20k	0.0020% R$ 2.5m
Arthur Higgins	Independent Director	17.8yrs	US$347.75k	0.0017% R$ 2.1m
Louis Shapiro	Director	less than a year	keine Daten	keine Daten
Maria Hilado	Independent Director	6.3yrs	US$314.44k	0.00083% R$ 1.0m
Michael Farrell	Independent Director	9.9yrs	US$342.52k	0.0010% R$ 1.2m
Devdatt Kurdikar	Director	less than a year	keine Daten	keine Daten
Sreelakshmi Kolli	Independent Director	3.8yrs	US$382.35k	0.00050% R$ 622.5k
Syed Jafry	Independent Director	6.3yrs	US$367.52k	0.0020% R$ 2.5m

6.3yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: Z1BH34Die Vorstandsmitglieder gelten als erfahren (6.3 Jahre durchschnittliche Amtszeit).

Zimmer Biomet Holdings Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Zimmer Biomet Holdings, Inc. Appoints David Demartino as Senior Vice President, Investor Relations

Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024

Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors

Zimmer Biomet Holdings, Inc. Announces CEO Changes

Zimmer Biomet Holdings, Inc. Appoints Keri P. Mattox as Chief Communications and Administration Officer

Recent updates

Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Ending December 31, 2024

Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Zimmer Biomet Holdings, Inc. Appoints David Demartino as Senior Vice President, Investor Relations

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024, Payable on or About October 31, 2024

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2024

Zimmer Biomet Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announces an Equity Buyback for $2,000 million worth of its shares.

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024, Payable on or About July 31, 2024

Zimmer Biomet Holdings, Inc. Reiterates Financial Guidance for Current Full-Year 2024

Zimmer Biomet Holdings, Inc. to Report Q1, 2024 Results on May 02, 2024

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024

Zimmer Biomet Holdings, Inc. Announces U.S. Food and Drug Administration (FDA) 510(K) Clearance of the Rosa® Shoulder System for Robotic-Assisted Shoulder Replacement Surgery

Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for the First Quarter of 2024, Payable on or About April 30, 2024

Zimmer Biomet Holdings, Inc. Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Zimmer Biomet Holdings, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors

Zimmer Biomet Holdings, Inc. Approves Cash Dividend for the Fourth Quarter of 2023, Payable on or About January 31, 2024

Zimmer Biomet Holdings, Inc. Updates Revenue Guidance for the Year Ending December 31, 2023

Zimmer Biomet Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zimmer Biomet Holdings, Inc. Announces Quarterly Dividend for Third Quarter of 2023, Payable on or about October 31, 2023

Zimmer Biomet Holdings, Inc. Announces CEO Changes

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year 2023

Zimmer Biomet Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2023, Payable on July 31, 2023

Zimmer Biomet Holdings, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q4, 2022 Results on Feb 03, 2023

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) entered into a definitive agreement to acquire Embody, Inc. for approximately $300 million.

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2022, Payable on or About January 31, 2023

Zimmer Biomet Holdings, Inc. Expands Persona(R) Knee System Portfolio with FDA Clearance of Persona(R) Osseoti(R) Keel Tibia for Cementless Knee Replacement

Zimmer Biomet Holdings, Inc. Announces One-Year Data from mymobility® Clinical Study at 2022 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Zimmer Biomet Holdings, Inc. Receives FDA Clearance for Identity(TM) Shoulder System for Shoulder Replacement

Zimmer Biomet Holdings, Inc Approves Quarterly Cash Dividend, Payable on or About October 31, 2022

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Zimmer Biomet Holdings, Inc. Appoints Keri P. Mattox as Chief Communications and Administration Officer

Zimmer Biomet Holdings, Inc. Approves Quarterly Dividend for Second Quarter of 2022, Payable on or About July 29, 2022

Zimmer Biomet Holdings, Inc. Debuts First-Of-Its-Kind Artificial Intelligence Capabilities for Omni™ Suite Intelligent Operating Room

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022

Extremity Medical, LLC Files Patent Infringement Lawsuit Against Nextremity Solutions, Zimmer Biomet Holdings, Inc. and Zimmer, Inc

Zimmer Biomet Holdings, Inc. to Report Q1, 2022 Results on May 03, 2022

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 16, 2022

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. Announces New Data Supporting Clinical Benefits of Mymobility® with Apple Watch® At AAOS 2021

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2021

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Year Ending December 31, 2021

Zimmer Biomet Holdings, Inc. Announces Management Changes

Zimmer Biomet Holdings, Inc. Approves Quarterly Cash Dividend for the First Quarter of 2021, Payable on or About April 30, 2021

Zimmer Biomet Holdings, Inc. Announces Board Changes

Zimmer Biomet Holdings, Inc Appoints Vafa Jamali as CEO of 'NewCo'

Zimmer Biomet Holdings, Inc. Appoints Ellison (Ellie) M. Humphrey as Chief Transformation Officer

Zimmer Biomet Holdings, Inc. to Report Q4, 2020 Results on Feb 05, 2021

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) acquired A&E Medical Corporation from Vance Street Management LLC and others for approximately $250 million.

Zimmer Biomet Holdings, Inc. Announces Preliminary Results from mymobility® Clinical Study at 2020 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. to Report Q3, 2020 Results on Nov 06, 2020

Zimmer Biomet Holdings, Inc. to Report Q3, 2019 Results on Nov 05, 2019

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) completed the acquisition of remaining 41.18% stake in MedTech Société Anonyme from Bertin Nahum, Bpifrance Investissement and other shareholders.

Zimmer Biomet Holdings, Inc. Does Not Provide Updated Financial Guidance for 2020

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter